NEW YORK, NY (December 1, 2011) – Schrödinger announced today that it has reached a consultancy agreement with Mark Murcko whereupon Dr. Murcko will serve as a Senior Advisor to the company. In his advisory capacity, Dr. Murcko will play a key role in a wide range of projects, including providing a vision for new products development, serving as a liaison to leaders in pharma, as well as participating in drug discovery projects.

“We are very excited to have this opportunity to work even more closely with Mark,” said Schrödinger’s President, Dr. Ramy Farid, “we’ve already had a great working relationship with Mark on our Scientific Advisory Board, but this new arrangement will allow us to tap further into Mark’s vast experience in leading large cross-disciplinary teams in successful drug discovery programs.”